Literature DB >> 30070365

Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.

Ji Hye Min1,2, Jong Man Kim3, Young Kon Kim1, Tae Wook Kang1, Soon Jin Lee1, Gyu Seong Choi3, Seo-Youn Choi4, Soohyun Ahn5.   

Abstract

We intraindividually compared the efficacy of magnetic resonance imaging (MRI) with extracellular contrast agents (ECA-MRI) and MRI with hepatobiliary agents (HBA-MRI) for the diagnosis of hepatocellular carcinoma (HCC) using the Liver Imaging Reporting and Data System (LI-RADS). Between November 2016 and November 2017, we enrolled 91 patients with chronic liver disease who underwent both ECA-MRI and HBA-MRI within a 1-month interval for a first detected hepatic nodule on ultrasound. In total, 117 observations (95 HCCs, 19 benign lesions, and 3 other malignancies; median size, 18 mm) were identified with surgical resection. Two observers assessed two MRIs based on LI-RADS v2017, with consensus by a third observer. We then compared the diagnostic performance of LR-5 according to LI-RADS and modified LI-RADS. ECA-MRI had higher sensitivity (77.9% versus 66.3%) and accuracy (82.1% versus 72.6%) than HBA-MRI in the LR-5 category (P < 0.001). When applying either modified washout on the portal venous phase (PVP)/transitional phase (TP) of HBA-MRI or isointensity with a capsule during the PVP/delayed phase of ECA-MRI (illusional washout), 13 HCCs on HBA-MRI and 11 HCCs on ECA-MRI were correctly classified as HCC, while achieving 100% specificity. One cholangiocarcinoma was accurately classified only with HBA-MRI due to its targetoid appearance in the TP and hepatobiliary phase.
Conclusion: ECA-MRI showed better sensitivity and accuracy than HBA-MRI for the diagnosis of HCC with LI-RADS. We achieved better diagnostic performance when applying a modified washout on PVP/TP HBA-MRI and an illusional washout on ECA-MRI than we did with conventional criteria.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30070365     DOI: 10.1002/hep.30122

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.

Authors:  Jingbiao Chen; Sichi Kuang; Yao Zhang; Wenjie Tang; Sidong Xie; Linqi Zhang; Dailin Rong; Bingjun He; Ying Deng; Yuanqiang Xiao; Wenqi Shi; Kathryn Fowler; Jin Wang; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2020-10-11

2.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

3.  LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?

Authors:  Roberto Cannella; Federica Vernuccio; Michela Antonucci; Domenico Salvatore Gagliano; Francesco Matteini; Massimo Midiri; Giuseppe Brancatelli
Journal:  Eur Radiol       Date:  2021-09-20       Impact factor: 7.034

4.  Interrater reliability and agreement of the liver imaging reporting and data system (LI-RADS) v2018 for the evaluation of hepatic lesions.

Authors:  Ahmed S Abdelrahman; Sherihan S Madkour; Mena E Y Ekladious
Journal:  Pol J Radiol       Date:  2022-06-13

5.  Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?

Authors:  Sidong Xie; Yao Zhang; Jingbiao Chen; Ting Jiang; Weimin Liu; Dailin Rong; Lin Sun; Linqi Zhang; Bingjun He; Jin Wang
Journal:  Abdom Radiol (NY)       Date:  2021-11-13

6.  Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.

Authors:  Sahar Semaan; Naik Vietti Violi; Sara Lewis; Manjil Chatterji; Christopher Song; Cecilia Besa; James S Babb; M Isabel Fiel; Myron Schwartz; Swan Thung; Claude B Sirlin; Bachir Taouli
Journal:  Eur Radiol       Date:  2019-10-31       Impact factor: 5.315

7.  Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas.

Authors:  Seung-Seob Kim; Sunyoung Lee; Jin-Young Choi; Joon Seok Lim; Mi-Suk Park; Myeong-Jin Kim
Journal:  Abdom Radiol (NY)       Date:  2020-11

8.  LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data.

Authors:  Tae-Hyung Kim; Sungmin Woo; Ijin Joo; Mustafa R Bashir; Mi-Suk Park; Lauren M B Burke; Mishal Mendiratta-Lala; Richard K G Do
Journal:  Abdom Radiol (NY)       Date:  2021-05-23

Review 9.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

Review 10.  Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.

Authors:  Junghoan Park; Jeong Min Lee; Tae-Hyung Kim; Jeong Hee Yoon
Journal:  Clin Mol Hepatol       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.